Actively Recruiting
Phase III Trial Comparing Chemotherapy Plus Ovarian Suppression and Endocrine Therapy Versus Ovarian Suppression and Endocrine Therapy Alone in Premenopausal Women With Early-Stage ER-Positive, HER2-Negative Breast Cancer and Low to Intermediate Oncotype Recurrence Scores
Led by NRG Oncology · Updated on 2026-11-04
3960
Participants Needed
1276
Research Sites
130 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
CONDITIONS
Brief Title
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Research Team
D
Director Regulatory Affairs
N
Norman Wolmark, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here